Daniel Catenacci, MD of the University of Chicago Medicine discusses Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE.
EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that develops the next generation of cancer immunotherapy to treat multiple forms of cancer, today reported that in the Phase 2 expansion cohorts of the GRANITE and SLATE Phase 1/2 clinical trials, its neoantigen-based immunotherapies, it has started dosing patients.
The Phase 2 section of the GRANITE Phase 1/2 (GO-004) study involves a cohort for patients with microsatellite stable colorectal cancer (MSS CRC) who have advanced treatment with FOLFOX / FOLFIRI and a second cohort for patients with chemotherapy-advanced gastroesophageal cancer (GEA). The U.S. granted GRANITE the Fast Track designation. Administration of Food and Medications for MSS CRC therapy.
In the Phase 2 portion of the SLATE Phase 1/2 (GO-005) trial, the company started enrolling patients with non-small cell lung cancer with relevant KRAS mutations who had advanced prior immunotherapy and patients with tumors where there was a relevant TP53 mutation.
GRANITE and SLATE About
Neoantigen-based immunotherapies from Gritstone are designed to elicit a significant T-cell response (particularly CD8 + cytotoxic T cells) to mutation-derived tumor-specific neoantigens, or TSNA, detected by the company using its proprietary artificial intelligence platform Gritstone EDGETM and sequencing of tumor HLA peptides. In Nature Biotechnology, data demonstrating the neoantigen identification capabilities of EDGE was published.
GRANITE is the personalized immunotherapy of Gritstone consisting of two components: first, a priming adenoviral vector is used to supply a cassette of 20 patient-specific TSNA extracted from the patient's own tumor; and second, in a repeated boost series, the same personalized TSNA cassette is supplied using a self-amplifying RNA vector. In a Phase 1/2 clinical trial known as GO-004, GRANITE is being tested in conjunction with immune checkpoint blockade. The U.S. granted GRANITE the Fast Track designation. Administration of Food and Medications for MSS CRC therapy.
SLATE is "off-the-shelf" immunotherapy from Gritstone. To deliver a cassette of 20 shared TSNAs, it uses the priming adenoviral vector and the self-amplifying RNA vector, describing mutated gene sequences that are shared among patients (such as TP53 and K-RAS mutations). In a Phase 1/2 clinical study called GO-005, SLATE is being assessed in combination with immune control point blockade.